Prof. Aharon Popovtzer, Director of Hadassah’s Sharett Institute of Oncology, emphasized the immediate impact on patient care: "We are proud to provide cancer patients with the best molecular characterization and are convinced that it will immediately lead to an improvement in the quality of treatment for many patients". Comprehensive genomic profiling tests enable the identification of all types of genomic alterations within a tumor, shedding light on the intricate mechanisms of cancer development and growth. This precision in diagnosis empowers physicians to tailor treatments to individual patients, optimizing outcomes while minimizing unnecessary interventions.